Warning Letters As Public “Leverage” Should Prompt GMP Compliance – Troy
This article was originally published in The Gray Sheet
Executive Summary
FDA Chief Counsel Daniel Troy emphasized the integral value of warning letters as public notification to a company's customers and competitors in a recent address to the University of Georgia's annual GMP conference
You may also be interested in...
Allen, Azar & Troy: FDA Legal Partners Streamline Enforcement Activity
HHS' decision to elevate FDA warning letter oversight from the Office of Regulatory Affairs to the Office of the Chief Counsel signals an attempt to keep a tighter rein on the agency in the absence of a commissioner
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.